Biolase (FRA:BTH0) LT-Debt-to-Total-Asset : 0.36 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Biolase LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Biolase's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.36.

Biolase's long-term debt to total assets ratio declined from Dec. 2022 (0.38) to Dec. 2023 (0.36). It may suggest that Biolase is progressively becoming less dependent on debt to grow their business.

Biolase LT-Debt-to-Total-Asset Historical Data

The historical data trend for Biolase's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase LT-Debt-to-Total-Asset Chart

Biolase Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.44

0.27

0.38

0.36

Biolase Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.38	0.33	0.33	0.32	0.36

Biolase LT-Debt-to-Total-Asset Calculation

Biolase's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	11.512	/	32.188
	=	0.36

Biolase's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	11.512	/	32.188
	=	0.36

Biolase (FRA:BTH0) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Biolase LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Biolase's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolase (FRA:BTH0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (FRA:BTH0) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BIOL:USA BTH0:Germany

Address

27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610

Website

https://www.biolase.com

Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

Biolase (FRA:BTH0) Headlines

No Headlines